Patent ID: 8512705

Claim:
A method of suppressing a Th2-mediated immune response in a human subject comprising administering to a subject in need thereof an isolated antibody that specifically binds human and cyno TSLP, or a TSLP-binding fragment thereof, in an amount effective to block the biological activity of TSLP; wherein the antibody is selected from the group consisting of: (i) an antibody comprising the three CDR sequences set forth in SEQ ID NOs: 1, 2 and 3 and the three CDR sequences set forth in SEQ ID NOs: 4, 5 and 6; (ii) a monoclonal antibody that specifically binds to the epitope on human TSLP that is bound by the antibody produced by the hybridoma deposited as PTA-7951; and (iii) a monoclonal antibody that competitively inhibits binding by the antibody produced by the hybridoma deposited as PTA-7951 to human TSLP.